Inhalation Sciences secures new order worth 54,700 Euro
(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.
Inhalation Sciences has received an order valued at 54,700 Euro with a new customer in Europe developing a generic inhaled drug-device combination therapy. The project will carry out required regulatory testing through a trusted service partner, sourced by ISAB, that specializes in regulatory testing of inhalers.
The collaborative project is the first of its kind for ISAB and is in line with the company’s strategy of increased focus on research services. ISAB is well-placed to take on such projects, with a leading reputation and decades-long network in inhalation that enables it to source specialist partners for a wide range of inhalation clients.
The company has several other high-value partner projects in its pipeline, as well as IRS projects carrying out inhalation studies and services inhouse, using the company’s advanced suite of preclinical research instruments.
CEO Manoush Masarrat: “Inhalation R&D is a complex area, so research alliances are a typical and highly valued feature of the landscape. As recognized authorities in the field we are happy to enable and drive forward premium partnerships and research solutions like this one”.
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.email@example.com Mobile: +46 (0)73 628 9153Press release in PDF format